Myelodysplastic Syndromes: Diagnosis, Treatment, and Side Effect Management
Recorded on: October 24, 2024
Recorded on: October 24, 2024
2.5 CE Contact hours/Credits for nurses and social workers available until: October 21, 2026
Format: Non-interactive recorded webinar
Target Audience
Oncology nurse practitioners, nurses, and social workers involved in the care of patients with myelodysplastic syndromes (MDS).
Course content level for social workers: all levels
Description
This program covers the various types and subtypes of myelodysplastic syndromes (MDS), tests used to diagnose disease and monitor treatment of MDS, overarching goals of treatment for the types of MDS, approved and emerging treatment options for MDS, side effect management, and the role of the healthcare team when caring for these patients. Tune in to hear expert discussion on to understanding of MDS, early detection and treatment, and resources for educating and supporting patients, to foster improved patient outcomes.
Educational Objectives
After completing this activity, the participant should be better able to:
- Describe the various types and subtypes MDS
- Identify tests used to diagnose disease and monitor treatment of MDS
- Explain the overarching goals of treatment for the subtypes of MDS
- Explain approved and emerging treatment options for MDS, including stem cell transplantation, and the role of clinical trials
- Describe the healthcare professional’s role in managing patients with MDS
Faculty
Guillermo Montalban-Bravo. MD
Assistant Professor, Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, TX
Shilpa Paul, PharmD, BCOP
Clinical Pharmacist, Division of Pharmacy
The University of Texas MD Anderson Cancer Center
Houston, TX
Elizabeth Hubert, MS, APRN, FNP-C
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, TX
Continuing Education Information
Nursing Continuing Professional Development
Approval for nurses has been obtained by the National Office of The Leukemia & Lymphoma Society under Provider Number CEP 5832 to award 2.5 continuing education contact hours through the California Board of Registered Nursing.
Social Worker Continuing Education
The Leukemia & Lymphoma Society (LLS) Provider Number 1105, is approved as an ACE provider to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Regulatory boards are the final authority on courses accepted for continuing education credit. ACE provider approval period: 12/10/2023-12/10/2026. Social workers completing this course receive 2.5 clinical continuing education credits.
The Leukemia & Lymphoma Society (LLS) is recognized by the New York State Education Departments State Board for Social Work as an approved provider of continuing education for licensed social workers #0117. LLS maintains responsibility for the program. Social workers will receive 2.5 clinical CE contact hours for this activity.
Method of Participation
There are no fees for participating in or receiving credit for this CE activity. In order to receive credit, learners must participate in the entire CE activity, complete the activity posttest, evaluation form and your certificate of credit will be generated. A passing score of 70% or higher is needed to obtain credit.
If you have questions regarding your certificate, please contact Nicole Dane via email at ndane@kimeglobal.com.
Providers
This activity is provided by The Leukemia & Lymphoma Society.
Supporters
There is no commercial support associated with this CE activity.
Participants gain access to the webinar via the participation button above.
For questions, concerns, or for assistance for people with disabilities or grievances, please contact us at ProfEducation@LLS.org.